Hope Medicine Inc. (HopeMed) is a clinical-stage biotechnology company focused on developing innovative therapies targeting the prolactin receptor. Based in major innovation hubs in China, the company leverages a deep understanding of disease biology and translational medicine, stemming from decades of scientific research led by Professor Rui Ping Xiao at Peking University. HopeMed's core product, HMI 115, is a potential first-in-class human antibody aimed at treating endometriosis, androgenic alopecia, and other diseases associated with dysregulated prolactin signaling. The company operates in the biopharmaceutical sector, serving patients with unmet medical needs. Its business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through licensing agreements, such as the exclusive worldwide license with Bayer AG, and future sales of approved treatments.

Keywords: prolactin receptor, endometriosis, androgenic alopecia, HMI 115, clinical-stage, biotech, translational medicine, antibody therapy, China, biopharmaceutical.